Jones Financial Companies
INKT icon

Jones Financial Companies’s MiNK Therapeutics INKT Stock Holding History

Jones Financial Companies’s Portfolio INKT Stock Details INKT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$11 Hold
1
– – ﹤0.01% 4697
2025
Q4 		$11 Hold
1
– – ﹤0.01% 4375
2025
Q3 		$14 Hold
1
– – ﹤0.01% 4209
2025
Q2 		$7 Hold
1
– – ﹤0.01% 4018
2025
Q1 		$9 Buy
+1
New +$9 ﹤0.01% 3687

Other funds holding INKT

VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
LF
Longbow Finance Lutry, Switzerland $782M AUM 48.76% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
VFT
Vanguard Fiduciary Trust Malvern, Pennsylvania $396B AUM
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
SPIA
Steward Partners Investment Advisory New York $19.6B AUM 22.89% 1-Year Est. Return
PP
Paladin Partners Hartland, Wisconsin $139M AUM
AGWCA
Annis Gardner Whiting Capital Advisors Tampa, Florida $625M AUM 23.8% 1-Year Est. Return
TRCT
Tower Research Capital (TRC) New York $3.85B AUM 32.11% 1-Year Est. Return

Jones Financial Companies's INKT Position: Q1 2026 in Review

Jones Financial Companies held its MiNK Therapeutics (INKT) position steady in Q1 2026 at 1 share worth $11. The position accounts for ﹤0.01% of the portfolio, ranked #4697.

Jones Financial Companies first reported a position in INKT in Q1 2025 and has held it in 5 quarters since. The position peaked at $14 in Q3 2025. 23 funds tracked by Wall St. Rank hold INKT as of Q1 2026.

  • Jones Financial Companies held 1 share of MiNK Therapeutics worth $11 as of Q1 2026.
  • Jones Financial Companies left its MiNK Therapeutics share count unchanged in Q1 2026.
  • MiNK Therapeutics made up ﹤0.01% of Jones Financial Companies's portfolio in Q1 2026, its #4697 holding.
  • Jones Financial Companies first reported a position in MiNK Therapeutics in Q1 2025 and has held it in 5 quarters since.
  • Jones Financial Companies's MiNK Therapeutics position peaked at $14 in Q3 2025.
  • 23 funds tracked by Wall St. Rank held MiNK Therapeutics as of Q1 2026.

Based on Jones Financial Companies's 13F filing for Q1 2026, filed 15 May 2026.